Row centres on 2015 deal to restart mothballed tower then known as Pinnacle
Lipton Rogers has rubbished claims it reneged on an 拢11m payment to a man who claims to have helped broker the firm鈥檚 deal on 22 Bishopsgate.
The business said the claim, filed by Hamid Alqumairi and Middle East Real Estate Inc more than two years ago, is 鈥渨ithout any foundation and is factually inaccurate and misconceived鈥.
In a statement released to the press last week, Alqumairi claimed he had been a 鈥渃rucial middleman鈥 in the 2015 deal which saw Lipton Rogers and French investor AXA take over the project from a Saudi consortium and said he had been promised a fee for his role.
But in a statement to 好色先生TV, Lipton Rogers said: 鈥淔ar from being 鈥榖reaking news鈥, the press release concerns a dispute which is now eight years old and refers to a legal claim issued by Mr Alqumairi in February 2021, over two years ago.鈥
The developer accused Alqumairi of an attempt to 鈥渆xert improper pressure鈥 on the firm to settle 鈥渋n the face of insuperable difficulties Mr Alqumairi is facing with his legal claim鈥, adding that an application had been listed before the High Court next month to strike out the claim for his alleged non-compliance with court orders.
The City of London鈥檚 tallest tower, 22 Bishopsgate was finally finished by Multiplex in December 2020, more than a decade after it was first slated for completion.
Alqumairi added the project 鈥渃ould not have been completed鈥 without him and that he had been 鈥渋nstrumental in getting a workable design agreed鈥.
鈥淚 had a fair deal to reward me for these efforts, which needs to be honoured,鈥 he said, claiming he is owed 拢11.1m, which is 1% of the 拢1.1bn the AXA team is understood to have paid for the site.
According to the particulars of claim, Alqumairi would alternatively accept 拢6.2m 鈥渂eing 1% of the construction costs paid which it is understood totalled 拢620 million鈥.
Lipton Rogers and AXA took over the development of the stalled tower, then known as the Pinnacle, eight years ago after work on that scheme was mothballed in 2012 because of funding problems.
No comments yet